Related Experiment Video
Updated: Aug 8, 2026

Lipidomics and Transcriptomics in Neurological Diseases
Published on: March 18, 2022
Development and validation of LC-MS-based bioanalytical methods for oligonucleotide therapeutics: points to consider
Yuchen Sun1, Kosuke Saito1, Shin-Ichiro Nitta2
1Division of Medicinal Safety Science, National Institute of Health Sciences, 3-25-26 Tonomachi, Kawasaki-ku, Kawasaki City, Kanagawa, 210-9501, Japan.
Analyzing oligonucleotide therapeutics like antisense oligonucleotides and siRNAs requires specialized bioanalytical methods. This paper offers expert recommendations for liquid chromatography-mass spectrometry (LC-MS) to overcome unique challenges in their analysis.
Area of Science:
- Pharmaceutical Analysis
- Bioanalytical Chemistry
- Therapeutic Modality Development
Background:
- Oligonucleotide therapeutics (e.g., antisense oligonucleotides, siRNAs) possess unique physicochemical properties, posing challenges for existing bioanalytical methods.
- Current International Council for Harmonisation (ICH) M10 guidelines lack specific validation frameworks for these complex nucleic acid-based drugs.
- There is a critical need for targeted bioanalytical method development and validation strategies for oligonucleotide therapeutics.
Purpose of the Study:
- To provide comprehensive recommendations for developing and validating bioanalytical methods for oligonucleotide therapeutics.
- To address specific technical challenges encountered in liquid chromatography-mass spectrometry (LC-MS) analysis.
- To support regulatory submissions and promote global harmonization of bioanalytical standards.
Main Methods:
- Expert consensus and literature review by the Japan Agency for Medical Research and Development research groups.
- Focus on ion-pair reversed-phase LC-MS methodologies and emerging techniques like hybridization extraction.
- Adaptation of ICH M10 validation parameters with fit-for-purpose modifications.
Main Results:
- Identification of key challenges: mobile phase stability, metal adsorption, carryover, internal standard selection, and matrix effects.
- Development of strategies for sample preparation, chromatographic optimization, and mass spectrometric detection.
- Recommendations for adapting validation parameters to the unique nature of oligonucleotide therapeutics.
Conclusions:
- The white paper provides practical guidance for the development and validation of LC-MS bioanalytical methods for oligonucleotide therapeutics.
- These recommendations aim to facilitate regulatory submissions and ensure the quality of bioanalytical data.
- The proposed strategies contribute to the standardization and advancement of bioanalytical science in this rapidly growing field.
More Related Videos
10:33Efficient Purification and LC-MS/MS-based Assay Development for Ten-Eleven Translocation-2 5-Methylcytosine Dioxygenase
Published on: October 15, 2018
11:00Untargeted Metabolomics from Biological Sources Using Ultraperformance Liquid Chromatography-High Resolution Mass Spectrometry (UPLC-HRMS)
Published on: May 20, 2013